Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01690598 |
Recruitment Status
:
Completed
First Posted
: September 24, 2012
Last Update Posted
: June 10, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ovarian Cancer | Drug: Veliparib Drug: Topotecan | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 22 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Veliparib (ABT888) and Topotecan (Hycamtin®) for Patients With Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer With Negative or Unknown BRCA Status |
Study Start Date : | November 2012 |
Actual Primary Completion Date : | January 2015 |
Actual Study Completion Date : | February 2015 |

Arm | Intervention/treatment |
---|---|
Experimental: Veliparib and Topotecan |
Drug: Veliparib
Veliparib (tablet) twice daily on days 1-3, 7-9, and 14-16 in a 28 days cycle. In phase I the starting dose is 30 mg x 2.
Drug: Topotecan
2 mg/m² iv over 30 minutes on days 2, 8, and 15 in cycles of 28 days. Topotecan is dosed at a maximum body surface area of 2 m².
|
- Phase I: Maximum tolerated dose, dose limiting toxicity and thus recommend phase II dose of veliparib [ Time Frame: 1 month ]
- Phase II: To investigate response rates (based on either CA125 GCIG or RECIST criteria) of combination topotecan and veliparib (ABT888) in relapsed ovarian cancer with negative or unknown BRCA status [ Time Frame: Every three months, up to 3 years ]
- Progression free survival of ovarian cancer patients treated with topotecan and veliparib [ Time Frame: Every three months up to three years ]
- Overall survival of ovarian cancer patients treated with topotecan and veliparib [ Time Frame: Every three months, up to three years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically confirmed epithelial, primary fallopian or primary peritoneal cancer.
- Verified progression by either RECIST criteria and/or GCIG CA125 criteria after previous first line chemotherapy or progression after later lines of cytotoxic treatment.
-
Platinum resistance or partially platinum sensitive disease
- Relapsed within six months of prior first line/later lines of platinum-based therapy or
- Relapsed within six-twelve months of prior first line/later lines of platinum-based therapy
- Age ≥ 18 years.
- Performance status 0-2.
- Measurable disease by RECIST 1.1 or CA125 GCIG criteria
-
Adequate bone marrow function, liver function, renal function and coagulation parameters (within 7 days prior to enrollment):
- WBC ≥ 3.0 x 10^9/l or neutrophils (ANC) ≥ 1.5 x 10^9/l
- Platelet count ≥ 100 x 109/l
- Hemoglobin ≥ 9.7 g/dl (6 mmol/L)
- Serum bilirubin ≤ 1.5 x ULN
- Serum transaminases ≤ 2.5 x ULN
- Serum creatinine ≤ 1.5 x ULN
- Written informed consent.
- Tissue available for BRCAness analysis/BRCA mutation analysis.
Exclusion Criteria:
- Prior treatment with a PARP inhibitor.
- Patients with BRCA1/2 germline mutation.
- Platinum-refractory disease (disease that progressed or was stable during prior platinum therapy)
- Patients who have received (or are planning to receive) treatment with any other investigational agent, or who have participated in another clinical trial within 28 days prior to entering this trial.
- Pregnant or breast-feeding. For fertile women a negative pregnancy test at screening is mandatory.
- Fertile patients not willing to use acceptable and safe methods of contraception during and for 6 months after treatment
- Other present or previous malignancy except curatively treated cervical cancer stage I, non-melanotic skin cancer or other cancer with minimal risk of relapse. Previous breast cancer is allowed, if disease free follow-up at least five years prior to enrollment.
- CNS metastasis.
- History of any chronic medical or psychiatric condition or laboratory abnormality, which is not medically controlled or in the opinion of the Investigator may increase the risks associated with study drug administration (e.g. diabetes, cardiac diseases, hypertension, renal or liver disease).
- Allergy to the ingredients of the study medication.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01690598
Denmark | |
Department of Oncology, Vejle Hospital | |
Vejle, Denmark, DK-7100 |
Study Chair: | Anders Jakobsen, MD, DMSc | Vejle Hospital | |
Principal Investigator: | Hanne Kanstrup, MD | Vejle Hospital |
Responsible Party: | Vejle Hospital |
ClinicalTrials.gov Identifier: | NCT01690598 History of Changes |
Other Study ID Numbers: |
VeTo |
First Posted: | September 24, 2012 Key Record Dates |
Last Update Posted: | June 10, 2015 |
Last Verified: | June 2015 |
Keywords provided by Vejle Hospital:
Epithelial ovarian cancer BRCA mutation Platinum resistant Platinum sensitive Relapsed ovarian cancer |
Additional relevant MeSH terms:
Veliparib Ovarian Neoplasms Endocrine Gland Neoplasms Neoplasms by Site Neoplasms Ovarian Diseases Adnexal Diseases Genital Diseases, Female Genital Neoplasms, Female Urogenital Neoplasms |
Endocrine System Diseases Gonadal Disorders Topotecan Topoisomerase I Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Poly(ADP-ribose) Polymerase Inhibitors |